Snow Storm Offers Sarepta Reprieve From FDA Advisory Committee
This article was originally published in The Pink Sheet Daily
No make-up date announced after weather worries force postponement, but Sarepta now has more time to contemplate answers to FDA questions about its Duchenne muscular dystrophy candidate eteplirsen.
You may also be interested in...
FDA wants another clinical trial for Duchenne muscular dystrophy treatment; focus moves to Sarepta's candidate, which gets committee review next week.
Only about one-third of biosimilars received a first-cycle approval from US FDA after product quality discussions during the mid-assessment-cycle meeting, according to an interim report on the biosimilar application review program.
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.